NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic Investor Brand Network

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE Therapeutics, is expected to be immediately accretive to revenue and EBITDA.
Cohen, serving the Sarasota-Bradenton area in Florida, specializes in treatments, including ketamine and TMS, for mood disorders, PTSD, and suicidal depression.
HOPE Therapeutics is expanding toward a target of 30 clinics with a $100 million run rate by the end of 2025.

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its wholly-owned subsidiary HOPE Therapeutics, Inc., a multi-site clinical care delivery organization, recently signed a binding letter of intent to acquire a 49% stake in Cohen and Associates, LLC, a respected neuropsychiatry clinic based in western Florida (https://ibn.fm/geIxF).

The agreement, announced on June 26, positions Cohen as a foundational clinic in the Sarasota-Bradenton region for HOPE’s growing network. Cohen and Associates, led by Dr. Rebecca Cohen, offers a comprehensive range of psychiatric care options, including ketamine infusions, Spravato, transcranial…